BMS 262084
Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator Bristol-Myers Squibb
- Class Anti-inflammatories; Antiasthmatics; Antirheumatics; Antithrombotics; Azetidines; Piperazines; Small molecules
- Mechanism of Action Factor XIa inhibitors; Tryptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Thrombosis
- Discontinued Allergic asthma
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Thrombosis in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Thrombosis in USA (PO)
- 10 Jul 2014 Phase-I clinical trials in Thrombosis in USA (Parenteral)